Alzheimer’s senescent cell combination therapy presents promise
Evidence from a Phase I trial suggests that the tyrosine kinase inhibitor dasatinib in combination with quercetin clears amyloid from the brain and lowers inflammation in the blood.
List view / Grid view
Evidence from a Phase I trial suggests that the tyrosine kinase inhibitor dasatinib in combination with quercetin clears amyloid from the brain and lowers inflammation in the blood.
An NIH-funded study has demonstrated that a combination of senolytic drugs can successfully reverse cell senescence in mice; providing potential avenue for future age-related treatment study.